Loading clinical trials...
Loading clinical trials...
FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of IBD
Hypothesis: Fecal Calprotectin will be useful in guiding the diagnosis and management of patients with Inflammatory Bowel Disease. Fecal Calprotectin can be utilized as an alternative to colonoscopy in the management of patients with Inflammatory Bowel Disease. Objectives: By means of a survey from the ordering physician we would assess: Primary Endpoint 1\. The Percentage of time that the Fecal Calprotectin result caused the physician to change the management of a patient. Secondary Endpoints 1. To determine if the Fecal Calprotectin result influenced the number of endoscopies performed 2. To correlate how well the Fecal Calprotectin correlates with Endoscopic findings when endoscopy was performed. 3. To assess the correlation between the Fecal Calprotectin level and symptoms as measured by the Harvey Bradshaw index or the partial Mayo Score (or full Mayo Score depending if endoscopy was performed).
Patients will be identified as eligible by the attending Gastroenterologist during the course of a usual consultation. Patients will be referred to the research nurse in the doctor's office for further information regarding the study and informed consent will be obtained by the research nurse. Upon enrollment, the physician or the research nurse will complete an online requisition form with a unique code which will provide the baseline data. The patient will be provided with the Easy Sampler™ collection kit and instructions on the use of this kit and location on where to send the specimen. The nurse will then send an email to the research nurse in the originating physician's office with the result of the calprotectin assay. The research nurse will review the result with the physician. After physician review, either the physician or the research nurse will then complete a follow up survey online. After completion of the assays and surveys, the data will be tabulated electronically from the online website and analyzed by the PI and/or co-investigators.
Age
19 - No limit years
Sex
ALL
Healthy Volunteers
No
GI Research Institute (GIRI)
Vancouver, British Columbia, Canada
Start Date
September 1, 2012
Primary Completion Date
March 1, 2013
Completion Date
September 1, 2013
Last Updated
June 9, 2014
289
ACTUAL participants
Lead Sponsor
University of British Columbia
NCT06226883
NCT07207200
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07271069